UNC Lineberger News

UNC researchers find final pieces to the circadian clock puzzle

UNC researchers find final pieces to the circadian clock puzzle

Sixteen years after scientists found the genes that control the circadian clock in all cells, the lab of UNC’s Aziz Sancar, MD, PhD, discovered the mechanisms responsible for keeping the clock in sync.

UNC researchers find final pieces to the circadian clock puzzle - Read More…

Damania appointed Assistant Dean for Research

Damania appointed Assistant Dean for Research

Blossom Damania, PhD, professor of microbiology and immunology, has been named Assistant Dean for Research at the UNC School of Medicine, effective immediately.

Damania appointed Assistant Dean for Research - Read More…

Basch contributes to new ASCO guidelines for prostate cancer treatment

Basch contributes to new ASCO guidelines for prostate cancer treatment

New clinical guidelines have been announced for the treatment of men with metastatic castration-resistant prostate cancer (CRPC) by the American Society of Clinical Oncology (ASCO) and Cancer Care Ontario (CCO). Ethan Basch, MD, director of the Cancer Outcomes Research Program at UNC Lineberger Comprehensive Cancer Center, served as the co-chair of the ASCO/CCO expert panel that developed the guideline.

Basch contributes to new ASCO guidelines for prostate cancer treatment - Read More…

UNC researchers find new genetic target for a different kind of cancer drug

UNC researchers find new genetic target for a different kind of cancer drug

Upstream of the proteins that cancer cells use to proliferate sits RBM4, a gene-splicing protein that UNC researcher Zefeng Wang, PhD, discovered is drastically reduced in human lung and breast cancer cells.

UNC researchers find new genetic target for a different kind of cancer drug - Read More…

Popular cancer drug target implicated in cardiovascular defects

Popular cancer drug target implicated in cardiovascular defects

Research led by UNC’s Kathleen Caron, PhD, shows that halting the protein CXCR7 leads to over activation of adrenomedullin, a hormone needed at proper levels for normal cardiovascular development

Popular cancer drug target implicated in cardiovascular defects - Read More…

Changing the face of clinical trials

Changing the face of clinical trials

UNC Lineberger secures three major NCI grants to advance the nation’s clinical trials program.

Changing the face of clinical trials - Read More…

Anders presents at 13th Annual Round Asia Oncology Forum

Anders presents at 13th Annual Round Asia Oncology Forum

Carey Anders, MD, UNC Lineberger member and associate professor, was a presenter and moderator at The 13th Annual Round Asia Oncology Forum (RAOF) in Hong Kong on August 29 - 30, 2014. The theme of this year’s forum was “Expanding our armory in personalized cancer treatment.”

Anders presents at 13th Annual Round Asia Oncology Forum - Read More…

Eshelman gives $3 million gift to Center for Integrative Chemical Biology and Drug Discovery

Eshelman gives $3 million gift to Center for Integrative Chemical Biology and Drug Discovery

The UNC Eshelman School of Pharmacy has received a $3 million gift from philanthropist and pharmaceutical-industry executive Fred Eshelman. Eshelman’s gift will support the work of the School’s Center for Integrative Chemical Biology and Drug Discovery, led by UNC Lineberger member Stephen Frye, PhD. The center is dedicated to evaluating and developing potential drug targets discovered by UNC faculty.

Eshelman gives $3 million gift to Center for Integrative Chemical Biology and Drug Discovery - Read More…

2014 University Cancer Research Fund Innovation Awards announced

Six researchers have been awarded 2014 University Cancer Research Fund (UCRF) Innovation Awards for promoting innovative and new ideas in cancer research at the University of North Carolina at Chapel Hill.

2014 University Cancer Research Fund Innovation Awards announced - Read More…